Health Canada "passes the buck" on diabetes drug, researcher charges

Eggertson, Laura
February 2011
CMAJ: Canadian Medical Association Journal;2/8/2011, Vol. 183 Issue 2, pE75
Academic Journal
The article reports on the outcome of Health Canada's efforts in managing the use of rosiglitazone or Avandia drugs in Glaxosmithkline Inc. and the U.S. Food and Drug Administration (FDA). Doctor David Juurlink, a scientist, states that the decision of Health Canada to restrict the use of rosiglitazone charge doctors to handle the safety use of the drugs. However, the potency of Health Canada restriction is still unmet due to unawareness of many doctors in the health risks of rosiglitazone.


Related Articles

  • FDA issues hold on much- debated Avandia study.  // Adirondack Daily Enterprise;7/24/2010, Vol. 117 Issue 174, pB7 

    The article reports on a hold on study issued by the U.S. Food and Drug Administration (FDA) to update researchers on the safety information about the drug Avandia.

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;1/14/2012, Issue 1384, p3 

    This section offers news briefs related to drug safety regulations. Health Canada has issued a warning about a significant labelling error in the French dosing directions for a Vita Health product. A single shared risk evaluation and mitigation strategy for the transmucosal immediate-release...

  • Avandia Gets Positive Vote, But It May Be too Late to Help. Serebrov, Mari // BioWorld Today;6/7/2013, Vol. 24 Issue 109, p1 

    This article reports on the decision of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs and the Drug Sfety and Risk Management Advisory Committees to remove the restrictions on the prescribing of GlaxoSmithKline PLC's diabetes drug Avandia (rosiglitazone)....

  • Critics Press FDA to Act on Evidence of Rosiglitazone's Cardiac Safety Issues. Mitka, Mike // JAMA: Journal of the American Medical Association;6/16/2010, Vol. 303 Issue 23, p2341 

    In this article, the author discusses the oversight of the U.S. Food and Drug Administration (FDA) over safety issues surrounding the rosiglitazone drug as of June 16, 2010. Critics reference findings from several meta-analyses and observational studies which showed that the drug is associated...

  • TIME TO END THE TYRANNY. Emord, Jonathan W. // USA Today Magazine;Feb2011, Vol. 139 Issue 2789, p16 

    This article endorses the removal of the U.S. Food and Drug Administration (FDA) from the drug evaluation equation. It criticizes the FDA for failing to prevent the entry of unsafe drugs to the market. It cites the decision of the FDA to approve the drug Avandia from GlaxoSmithKline despite the...

  • FDA Eases Restrictions on the Glucose-Lowering Drug Rosiglitazone. Mitka, Mike // JAMA: Journal of the American Medical Association;12/25/2013, Vol. 310 Issue 24, p2604 

    The article reports on the announcement by the U.S. Food and Drug Administration (FDA) on November 25, 2013 that it was lifting restrictions on prescribing and use of the blood glucose-lowering drug, rosiglitazone. It mentions the success of the sale of the drug, which was manufactured by...

  • Critic suggests Health Canada lacks guts to pull drug.  // Reactions Weekly;2/12/2011, Issue 1338, p3 

    The article considers the views of David Juurlink, head of clinical pharmacology and toxicology at the Sunnybrook Health Sciences Center in Toronto, Ontario, on the measures taken by Health Canada on restricting the use of rosiglitazone. According to Juurlink, Health Canada should have suspended...

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;9/1/2012, Issue 1417, p3 

    This section offers news briefs on the pharmaceutical industry as of September 1, 2012. The British Medicines and Healthcare products Regulatory Agency (MHRA) announced the contraindication of simvastatin with ciclosporin, danazol and gemfibrozil. Health Canada has endorsed safety information on...

  • They're Approved, But Are They Safe? Park, Alice // Time International (South Pacific Edition);7/12/2010, Vol. 176 Issue 2, p9 

    The article discusses drug research results which has raised questions about the drug approval process used by the U.S. Food and Drug Administration (FDA). Research studies finding significant safety issues regarding the side effects associated with the diabetes drug Avandia (rosiglitazone) and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics